Cargando…
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
BACKGROUND: The benefit of precision medicine based on relatively limited gene sets and often-archived samples remains unproven. PERMED-01 (NCT02342158) was a prospective monocentric clinical trial assessing, in adults with advanced solid cancer, the feasibility and impact of extensive molecular pro...
Autores principales: | Bertucci, François, Gonçalves, Anthony, Guille, Arnaud, Adelaïde, José, Garnier, Séverine, Carbuccia, Nadine, Billon, Emilien, Finetti, Pascal, Sfumato, Patrick, Monneur, Audrey, Pécheux, Christophe, Khran, Martin, Brunelle, Serge, Mescam, Lenaïg, Thomassin-Piana, Jeanne, Poizat, Flora, Charafe-Jauffret, Emmanuelle, Turrini, Olivier, Lambaudie, Eric, Provansal, Magali, Extra, Jean-Marc, Madroszyk, Anne, Gilabert, Marine, Sabatier, Renaud, Vicier, Cécile, Mamessier, Emilie, Chabannon, Christian, Pakradouni, Jihane, Viens, Patrice, André, Fabrice, Gravis, Gwenaelle, Popovici, Cornel, Birnbaum, Daniel, Chaffanet, Max |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132379/ https://www.ncbi.nlm.nih.gov/pubmed/34006291 http://dx.doi.org/10.1186/s13073-021-00897-9 |
Ejemplares similares
-
Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial
por: Billon, Emilien, et al.
Publicado: (2022) -
Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial
por: Sabatier, Renaud, et al.
Publicado: (2022) -
Comparative genomic analysis of primary tumors and metastases in breast cancer
por: Bertucci, François, et al.
Publicado: (2016) -
Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study
por: Sabatier, Renaud, et al.
Publicado: (2022) -
Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study
por: Boudin, Laurys, et al.
Publicado: (2016)